DBV Technologies Reports Positive VITESSE Data for VIASKIN Peanut Patch
CHÂTILLON, France, June 8, 2026 DBV Technologies announced new positive clinical findings from its Phase 3 VITESSE study evaluating...
atopic dermatitis
Advertisement
Apogee Therapeutics Lands $1.3B Blackstone Deal
SAN FRANCISCO and BOSTON, May 27, 2026 Apogee Therapeutics announced a landmark $1.3 billion strategic financing collaboration with Blackstone...
Apogee to Reveal Phase 2 Zumilokibart AD Data
SAN FRANCISCO and BOSTON, May 26, 2026 Apogee Therapeutics announced it will report Part B 16-week clinical data from...
Elanco Launches Befrena for Canine Allergy and Itch Relief
Indianapolis, Indiana, USA – May 18, 2026 Elanco Animal Health Incorporated announced the phased U.S. launch of Befrena™ (tirnovetmab),...
Castle Biosciences Wins 2026 Genomics Innovation Award
FRIENDSWOOD, Texas, May 12, 2026 Castle Biosciences announced that its AdvanceAD-Tx™ gene expression profiling test received the prestigious 2026...
Advertisements
Alkermes Reports Strong Phase 3 LUMRYZ Trial Data
DUBLIN, Ireland, May 12, 2026 Alkermes announced positive topline results from the pivotal REVITALYZ Phase 3 clinical trial evaluating...
TRexBio Reports New TRB-061 Data for Atopic Dermatitis
SOUTH SAN FRANCISCO, Calif., May 7, 2026 TRexBio announced new late-breaking translational and preclinical data supporting TNFR2 agonism as...
Incyte Opzelura Shows Durable Atopic Dermatitis Benefit
WILMINGTON, Del., May 7, 2026 Incyte announced positive 24-week long-term results from the Phase 3 TRuE-AD4 clinical trial evaluating...
Bambusa Therapeutics Completes BBT001 Trial Enrollment
BOSTON, MASSACHUSETTS, April 30, 2026 Bambusa Therapeutics has announced the successful completion of patient enrollment in its Phase 1b/2a...
TRexBio Advances TRB-061 Phase 1b Trial for Atopic Dermatitis
SOUTH SAN FRANCISCO, April 29, 2026 TRexBio, Inc. has announced that the first patient has been dosed in the...
Advertisement
